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Abstract
Objective: We have previously analyzed protein proﬁ  les using Surface Enhanced Laser Desorption and Ionization Time-Of-Flight 
Mass Spectroscopy (SELDI-TOF-MS) [Kozak et al. 2003, Proc. Natl. Acad. Sci. U.S.A. 100:12343–8] and identiﬁ  ed 
3 differentially expressed serum proteins for the diagnosis of ovarian cancer (OC) [Kozak et al. 2005, Proteomics, 5:4589–96], 
namely, apolipoprotein A-I (apoA-I), transthyretin (TTR) and transferin (TF). The objective of the present study is to determine 
the efﬁ  cacy of the three OC biomarkers for the detection of early stage (ES) OC, in direct comparison to CA125.
Methods: The levels of CA125, apoA-I, TTR and TF were measured in 392 serum samples [82 women with normal ovaries 
(N), 24 women with benign ovarian tumors (B), 85 women with ovarian tumors of low malignant potential (LMP), 126 
women with early stage ovarian cancer (ESOC), and 75 women with late stage ovarian cancer (LSOC)], obtained through 
the GOG and Cooperative Human Tissue Network. Following statistical analysis, multivariate regression models were built 
to evaluate the utility of the three OC markers in early detection.
Results: Multiple logistic regression models (MLRM) utilizing all biomarker values (CA125, TTR, TF and apoA-I) from 
all histological subtypes (serous, mucinous, and endometrioid adenocarcinoma) distinguished normal samples from LMP 
with 91% sensitivity (speciﬁ  city 92%), and normal samples from ESOC with a sensitivity of 89% (speciﬁ  city 92%). MLRM, 
utilizing values of all four markers from only the mucinous histological subtype showed that collectively, CA125, TTR, TF 
and apoA-I, were able to distinguish normal samples from mucinous LMP with 90% sensitivity, and further distinguished 
normal samples from early stage mucinous ovarian cancer with a sensitivity of 95%. In contrast, in serum samples from 
patients with mucinous tumors, CA125 alone was able to distinguish normal samples from LMP and early stage ovarian 
cancer with a sensitivity of only 46% and 47%, respectively. Furthermore, collectively, apoA-I, TTR and TF (excluding 
CA-125) distinguished i) normal samples from samples representing all histopathologic subtypes of LMP, with a sensitivity 
of 73%, ii) normal samples from ESOC with a sensitivity of 84% and iii) normal samples from LSOC with a sensitivity of 
97%. More strikingly, the sensitivity in distinguishing normal versus mucinous ESOC, utilizing apoA-I, TF and TTR 
(CA-125 excluded), was 95% (speciﬁ  city 86%; AUC 95%).
Conclusions: These results suggest that the biomarker panel consisting of apoA-I, TTR and TF may signiﬁ  cantly improve 
early detection of OC.
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Introduction
Ovarian cancer has the highest mortality rate of all the gynecologic malignancies worldwide. With no adequate 
screening tests, early diagnosis—the most signiﬁ  cant prognostic factor—continues to elude the clinician. 
Presently, over 85% of patients with ovarian cancer are diagnosed with Stage III or IV disease [1].
Serum cancer antigen 125 (CA125), a high molecular weight glycoprotein, is currently the best 
clinical marker for papillary serous adenocarcinoma of the ovary in the postmenopausal age group. 370
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Table 1. Clinical characteristics and age distribution of 392 study samples.
 Age  Pathology
Diagnostic Clear
group Number  Mean  SD  Median  cell  Endometrioid  Mucinous  Serous  Other
N 82  42.5  10.7  43         
B 24  53.0  18.6  50      10  1  13
LMP 85  50.5  14.9  50    1  41  42  1
ES 126  56.1  13.3  54  15  46  19  25  21
LS 75  59.1  12.5  59  6  10  1  42  16
However it is a consistently poor diagnostic tumor 
biomarker in premenopausal women, non-serous 
histologies, and early stage diseases. Only 
50%–60% of women with early stage ovarian 
cancer will demonstrate elevated serum levels of 
CA125 [2]. Falsely elevated levels are common in 
a number of benign conditions such as pregnancy, 
uterine ﬁ  broids, or intra-abdominal infections and 
other intraperitoneal pathology [3]. The identiﬁ  ca-
tion of more sensitive and speciﬁ  c biomarkers for 
the early detection of ovarian cancer would clearly 
be immediately beneﬁ  cial.
Proteomic-based approaches have been utilized 
in an attempt to detect early-stage ovarian cancer 
patients, and monitor biologic responses to therapy 
[4], [5]. Serum protein proﬁ  ling at different stages 
in disease progression, or along the course of 
therapy, offers a new paradigm for detecting and 
treating ovarian cancer [6–10]. We have previously 
analyzed protein proﬁ  les using Surface Enhanced 
Laser Desorption and Ionization Time-Of-Flight 
Mass Spectroscopy (SELDI-TOF-MS) and identi-
ﬁ  ed 3 differentially expressed serum proteins for 
the detection of ovarian cancer [6], [7]. These were 
apoA-I, TTR, and TF. In the present study, we 
analyzed an additional 392 serum samples from 
patients obtained through the GOG and Coopera-
tive Human Tissue Network for the levels of 
markers that included CA125, in addition to the 
previously described markers.
Materials and Methods
Serum samples were obtained through the Gyne-
cological Oncology Group (GOG) and Cooperative 
Human Tissue Network. Samples were collected 
preoperatively following the standard GOG pro-
tocol (GOG 199 protocol) from patients with 
benign, borderline and malignant ovarian tumors. 
The 392 serum samples utilized in the present study 
included 82 women with normal ovaries (N), 24 
women with benign ovarian tumors (B), 85 women 
with ovarian tumors of low malignant potential 
(LMP), 126 women with early stage ovarian can-
cer (ESOC), and 75 women with late stage ovarian 
cancer (LSOC). The age and pathology distribution 
of the samples are provided in Table 1.
The levels of each individual protein marker 
(CA125, apoA-I, TTR, TF) were measured on all 
serum samples. The Immulite 1000 was used to 
measure CA125 level by using chemiluminescence 
technology and the Hitachi 912 was used to mea-
sure apoA-I, TTR and TF levels based on immu-
noturbimetry technology. The reagents were 
purchased from Diagnostics Product Corporation 
and Roche. A separate dataset was compiled for 
external-validation purposes from serum collected 
from patients with breast cancer, colon cancer and 
atherosclerosis.
Statistical analysis of the levels of each of the 
individual markers (apoA-I, TTR, TF, and CA125) 
was performed using the Kruskal-Wallis non-
parametric rank sum test and Mann-Whitney U tests 
to compare marker levels across ovarian cancer stage. 
Multivariate logistic regression models (MLRM) 
were built to predict N vs. low malignant potential 
(LMP) and N vs. ESOC and LSOC. Model prediction 
‘cut-points’ were also determined by maximizing 
speciﬁ  city and sensitivity with equal weight. We then 
compared MLRM sensitivity, speciﬁ  city and area 
under the receiver operator curve (AUC). AUC is a 
cut-point independent measure of predictive value.
Age-matched (51.5 ± 7.5) sera from a separate 
dataset that included normals, patients with early 
stage ovarian cancer, breast and colon cancers, and 
atherosclerosis were then standardized based on the 
normals in each dataset, assuming a scalar multiplier 
for each type of measurement (CA125, apoA-I, TF, 
and TTR). To compute the standardization, 
multipliers and perform multivariate statistical tests, 371
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extreme outliers were removed using a standard 
outlier detection procedure [10], [11]. The multi-
variate MANOVA and MLRM prediction was then 
employed to demonstrate marker level differences 
between these external validation patients and the 
ovarian cancer patients. To determine statistical 
signiﬁ  cance, we assumed a 5% Type I Error rate and 
did not control for multiple comparisons. All tests 
were performed using the R statistical package.
Results
Prior to analyzing for the new biomarker panel, 
the serum was ﬁ  rst tested for CA125 levels, which 
is the current gold standard biomarker for ovarian 
cancer. Although CA125 had 99% speciﬁ  city for 
all the samples tested, the sensitivity was only 62% 
in distinguishing LMP from normal subjects, and 
76% in distinguishing ESOC from normal subjects 
(Table 2). Moreover, in serum samples from 
patients with mucinous tumors, CA125 was able 
to distinguish normal samples from LMP and 
ESOC with a sensitivity of only 46% and 47%, 
respectively (Table 2).
The expression of each protein from the bio-
marker panel is signiﬁ  cantly different across sub-
groups compared to normal (Fig. 1). Multiple 
logistic regression models (MLRM) were con-
structed utilizing all biomarker values (CA125, 
TTR, TF and apoA-I) from all histological subtypes 
(serous, mucinous, and endometrioid adenocarci-
noma). Collectively, the four markers (CA125, 
TTR, TF and apoA-I) distinguished normal sam-
ples from LMP with 91% sensitivity (speciﬁ  city 
92%; AUC 97%), normal samples from ESOC with 
a sensitivity of 89% (speciﬁ  city 97%; AUC 98%); 
and normal samples from LSOC with a sensitivity 
of 97% (speciﬁ  city 99%; AUC 99%) (Table 3).
Interestingly, when a similar logistic regression 
analysis was performed evaluating only the mucinous 
histology subgroup, the results suggested greater 
sensitivity and speciﬁ  city in the ability of the bio-
markers to distinguish serum from normal subjects 
versus patients with ESOC (Table 3). MLRM, utiliz-
ing all biomarker values (CA125, TTR, TF and 
apoA-I), from only the mucinous histological sub-
type showed that collectively, CA125, TTR, TF and 
apoA-I were able to distinguish normal samples from 
mucinous LMP with 90% sensitivity (speciﬁ  city 
91%; AUC 96%). In contrast, these four biomarkers 
when used together, distinguished serum samples 
from normal subjects versus patients with early stage 
mucinous ovarian cancer with a sensitivity of 95% 
(speciﬁ  city 92%; AUC 97%) (Table 3).
We next assessed the utility of the new biomarker 
panel consisting of TTR, TF and apoA-I for the early 
detection of OC. MLRM was constructed using the 
values for apo-A1, TF and TTR (CA125 excluded, 
Table 4). Collectively, apoA-I, TTR and TF distin-
guished i) normal samples from samples represent-
ing all histopathologic subtypes of LMP, with a 
sensitivity of 73% (speciﬁ  city 83%; AUC 81%), ii) 
normal samples from samples with ESOC with a 
sensitivity of 84% (speciﬁ  city 85%; AUC 90%), and 
iii) normal samples from LSOC with a sensitivity 
of 97% (speciﬁ  city 86%; AUC 96%). More strik-
ingly, the sensitivity in distinguishing normal versus 
mucinous early stage ovarian cancer, utilizing 
apoA-1, TF and TTR (CA125 excluded), was 95% 
(speciﬁ  city 86%; AUC 95%) (Table. 4).
Table 2. Speciﬁ  city, sensitivity and AUC values derived 
from CA125 levels 35 units/ml for distinguishing nor-
mal subjects (n = 82) from LMP, ESOC, LSOC, muci-
nous LMP and mucinous ESOC.
Groups Speciﬁ  city  Sensitivity  AUC
LMP (all subtypes,  0.99  0.62  0.80 
n = 85)
ESOC (all subtypes,  0.99  0.76  0.87
n = 126)
LSOC (all subtypes,  0.99  0.95  0.97
n = 75)
LMP (mucinous,  0.99  0.46  0.73
n = 41)
ESOC (mucinous,  0.99  0.47  0.73
n = 19)
Table 3. Speciﬁ  city, sensitivity and AUC values derived 
from all covariates (apoA-I, TTR, TF and CA125) levels 
for distinguishing normal subjects (n = 82) from LMP, 
ESOC, LSOC, mucinous LMP and mucinous ESOC.
Groups   Speciﬁ  city Sensitivity AUC
N vs. LMP (all   0.92  0.91  0.97
subtypes, n = 85)
N vs. ES (all   0.97  0.89  0.98
subtypes, n = 126)
N vs. LS (all   0.99  0.97  0.99
subtypes, n = 75)
N vs. LMP    0.91  0.90  0.96
(mucinous, n = 41)
N vs. ES   0.92  0.95  0.97
(mucinous, n = 19)372
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Figure 1. The comparisons of differential protein expression in serum across subgroups. Plotted values are 1 standard error. Using Kruskal-
Wallis ranks sum test, expression for each protein signiﬁ  cantly differs across subgroups from normal, all p-values < 0.001.
To further validate the disease-speciﬁ  city of the 
three biomarkers, we examined serum levels for 
apoA-I, TTR and TF in 71 additional subjects that 
included normal (18), breast cancer (18), colon 
cancer (8), atherosclerosis (9), and early stage OC 
(18) (Fig. 2). Multivariate comparison of apoA-I, 
TF and TTR demonstrate notable differences 
between diseases (Fig. 2). Using the MLRMs 
constructed to make predictions on these indepen-
dent data resulted in the ROC curve (Fig. 3), and 
demonstrated a speciﬁ  city of 92%, sensitivity of 
94% and AUC of 0.98.
Discussion
The majority of patients with ovarian cancer are diag-
nosed with Stage III or IV disease. Unfortunately, 
there are no adequate screening tests for the early 
detection of ovarian cancer and as a result, the 
diagnosis of ovarian cancer eludes the clinician. 
Not surprisingly, ovarian cancer is associated with 
the highest mortality rate among gynecologic 
malignancies. [1].
Serum cancer antigen 125 (CA125), a high 
molecular weight glycoprotein, is currently the best 
clinical marker for papillary serous adenocarcinoma 
of the ovary in the postmenopausal age group. 
However it is a consistently poor diagnostic tumor 
biomarker in premenopausal women, non-serous 
histologies, and early stage diseases. Only 
50%–60% of women with early stage ovarian 
cancer will demonstrate elevated serum levels of 
CA125 [2]. Falsely elevated levels are common in 
a number of benign conditions such as pregnancy, 373
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uterine ﬁ  broids, or intra-abdominal infections and 
other intraperitoneal pathology [3]. The identiﬁ  ca-
tion of more sensitive and speciﬁ  c biomarkers for 
the early detection of ovarian cancer would clearly 
be immediately beneﬁ  cial.
Since CA125 is the gold standard biomarker for 
ovarian cancer, we measured CA125 levels in all 
the study samples. CA125 levels alone distin-
guished N from LMP with a sensitivity of 62% and 
N from ESOC with a sensitivity of 76% (Table 2). 
Furthermore, when the mucinous subsets were 
analyzed, CA125 levels distinguished N from LMP 
and ESOC with a sensitivity of 46% and 47% 
respectively (Table 2). These numbers are in agree-
ment with previously reported data for CA125 
[12]. As one of the goals of this study was to test 
the efﬁ  cacy of the three biomarkers we recently 
identiﬁ  ed for the detection of OC, we examined 
whether the three markers, apoA-I, TTR and TF 
could improve upon the CA125 based measure-
ments. Using all the four markers (apoA-I, TTR, 
TF and CA125) and all of the 392 samples we 
analyzed for this study, we observed a 29% 
improvement in sensitivity for the detection of 
LMP, and a 13% improvement in sensitivity for 
the detection of ESOC (Table 3). More importantly, 
the four markers collectively improved the detec-
tion of LMP and ESOC of the mucinous subtype 
by 44% and 48%, respectively, compared to normal 
subjects (Table 3). These results warrant further 
studies to evaluate the new biomarkers in the early 
detection of OC.
Interestingly, there exists a link between OC 
and each of the three biomarkers, apoA-I, TTR 
and TF [13], [14], [15]. ApoA-I (28 kDa) is the 
major protein constituent of high density lipopro-
tein. Decreased apoA-I levels were previously 
reported in the serum of patients with both ovarian 
cancer [13], [14], [15] as well as atherosclerosis 
[16]. Serum lipid and lipoprotein association with 
cancer has been reported in numerous studies [17], 
[18], [19]. The mechanism of this association 
remains unclear at this time, however it has been 
proposed to be associated with free radical-mediated 
damage to cellular biomembranes resulting in lipid 
peroxidation. Malondiadlehyde (MDA) is a 
byproduct of lipid degradation. MDA-DNA 
adducts appear to be promutagenic, inducing 
mutations in oncogenes and tumor suppressor 
genes seen in human tumors [20]. TTR (13.9 kDa) 
is a secreted protein that functions as a binding 
protein to transport serum thyroxine, tri-iodothy-
ronine and retinol (vitamin A). TTR levels have 
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Figure 2. The standardized comparisons of differential protein expres-
sion in serum across different diseases. Plotted values are 1 standard 
error. Using a robust MANOVA analysis, CA125, apoA-I, TTR and 
TF are signiﬁ  cantly differ only in early stage ovarian cancer from 
normal samples, all p-values  0.0001.
Table 4. Multivariate logistic regression models using apoA-I, TF and TTR (CA-125 excluded), for either all hist-
opathologic subtypes or for mucinous subtype alone from 82 normal samples.
Groups  All histological subtypes  Mucinous subtype
 n  Speciﬁ  city  Sensitivity  AUC  n  Speciﬁ   city Sensitivity AUC
N vs. LMP  85  0.83  0.73  0.81  41  0.86  0.80  0.88
N vs. ESOC  126  0.85  0.84  0.90  19  0.86  0.95  0.95
N vs. LSOC  75  0.86  0.97  0.96  --  --  --  --374
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been reported to be inversely correlated to tumor 
volume in ovarian cancer [21]. Immunohistochem-
istry studies have shown levels of cellular retinal 
binding proteins to be decreased in ovarian cancers 
[22]. TF (79 kDa) is an iron binding transport 
protein, responsible for transporting iron from 
sites of iron absorption and heme degradation to 
areas of storage and utilization [23], [24]. TF has 
been previously reported to be decreased in serum 
of patients with ovarian cancer [25]. All of these 
molecules have been shown to play an important 
role in oxidative stress, for which there is myriad 
data linking to carcinogenesis [26], [27], [28], 
[29], [30].
In order to evaluate the direct efﬁ  cacy of the 
three biomarkers, apoA-I, TTR, and TF, in detect-
ing OC, we reevaluated the speciﬁ  city, sensitivity 
and AUC values without CA125 levels. We noted 
an improvement of 11% in sensitivity for the detec-
tion of LMP (compared to CA125 alone, Table. 2 
and Table 4) when samples from all histopathologic 
subtypes were analyzed, and an improvement of 
14% for the detection of LSOC (compared to 
CA125 alone, Table 2 and Table 4). Interestingly, 
we noted an improvement of 34% in sensitivity for 
the detection of LMP (compared to CA125 alone, 
Table 3 and Table 4) when mucinous histopatho-
logic subtypes alone were analyzed, and an 
improvement of 48% for the detection of LSOC 
(compared to CA125 alone, Table 3 and Table 4). 
These data further attest to the clear improvement 
(over CA125) of the new panel of biomarkers for 
the early detection of OC. These results further 
build on the work previously reported by Zhang 
et al. (2004), also utilizing SELDI-TOF-MS with 
similar methodology, in which a panel of biomark-
ers including apolipoprotein A1, and a truncated 
form of transthyretin (identiﬁ  ed from the m/z 
12828 peak, corresponding to a 12.9 kDa protein 
fragment), in combination with a cleavage factor 
of inter-a-trypsin inhibitor heavy chain H4 and 
CA125 saw a more modestly improved sensitivity 
(9%) for the detection of stage I/II ovarian cancer 
over CA125 alone [31]. It is interesting that our 
work identiﬁ  ed the m/z 13797 peak corresponding 
to the 13.9 kDa marker, which we identiﬁ  ed as the 
complete TTR protein product to be down-regu-
lated in early ovarian cancer.
More recently, to evaluate these markers in an 
independent study population, postdiagnostic/pre-
treatment serum samples were studied as part of 
the National Cancer Institute Immunodiagnostic 
Serum Bank; levels of various posttranslationally 
forms of transthyretin and apolipoprotein A1 were 
measured in addition to CA125. The mean levels 
of ﬁ  ve of the six forms of transthyretin were sig-
niﬁ  cantly lower in cases than in controls. The 
speciﬁ  city of a model including transthyretin and 
apolipoprotein A1 alone was high, 96.5%, but 
sensitivity was low, 52.4%. A class prediction 
algorithm using all seven markers, CA125, and age 
maintained high speciﬁ  city, 94.3%, but still rela-
tively low sensitivity, 78.6% [32]. It is interesting 
that our work identiﬁ  ed the m/z 13797 peak cor-
responding to the 13.9 kDa marker, which we 
identiﬁ  ed as the complete TTR protein product to 
be differentially expressed as down-regulated in 
early ovarian cancer.
Specificity 92%
Sensitivity 94% 
AUC 0.98
Figure 3. Receiver operating characteristic curve of multivariate predictive model using apoA-I, TTR and TF.375
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Finally, our data also suggest that apoA-I, TTR, 
and TF, when analyzed collectively, are unique to 
ovarian cancer (Fig. 2) and thus provide for the ﬁ  rst 
time a disease-speciﬁ  c multiple marker panel for the 
early detection of OC. In conclusion, we have shown 
that ApoA-I, TF, and TTR, in combination with 
CA125 in a multivariate predictive model, have the 
potential to improve the speciﬁ  city and sensitivity 
for the early detection of ovarian cancer over CA125 
alone, particularly for the mucinous histopathologic 
subtype. Further elucidation of the mechanisms and 
pathways by which ApoA-I, TF, and TTR, partici-
pate in the development of OC will not only be 
important for early detection but also ultimately 
provide targets for therapeutic intervention of OC.
Article Précis
Three serum biomarkers, Apolipoprotein A-I, Trans-
thyretin and Transferrin, combine with CA125 can 
be used to signiﬁ  cantly improve detection of early 
stage ovarian cancer over CA125 alone.
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